Mohamed H. Farah

Dr. Mohamed H. Farah

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Experimental Neurology
Verified
Journal Article
Closed access
BMBrett M. Morrison
Brett M. Morrison
ATAkivaga Tsingalia
Akivaga Tsingalia
SVSvetlana Vidensky
Svetlana Vidensky
YLYoungjin Lee
Youngjin Lee
LJLin Jin
Lin Jin
JRJeffrey D. Rothstein
Jeffrey D. Rothstein

23 June 2005 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
MFMohamed H. Farah
Mohamed H. Farah
SEStephen S. Easter
Stephen S. Easter

19 February 2021 in Neural Regeneration Research
Verified
Journal Article
Open access
KMKatherine L. Marshall
Katherine L. Marshall
MFMohamed H. Farah
Mohamed H. Farah
Nervous system disorders are prevalent health issues that will only continue to increase in frequency as the population ages. Dying-back axonopathy is a hallmark of many neurologic diseases and leads to axonal disconnection from their targets, which in turn leads to functional impairment. During the course of many of neurologic diseases, axons can regenerate or sprout in an attempt to reconnect with the target and restore synapse function. In amyotrophic lateral sclerosis (ALS), distal motor axons retract from neuromuscular junctions early in the disease-course before significant motor neuron death. There is evidence of compensatory motor axon sprouting and reinnervation of neuromuscular junctions in ALS that is usually quickly overtaken by the disease course. Potential drugs that enhance compensatory sprouting and encourage reinnervation may slow symptom progression and retain muscle function for a longer period of time in ALS and in other diseases that exhibit dying-back axonopathy. There remain many outstanding questions as to the impact of distinct disease-causing mutations on axonal outgrowth and regeneration, especially in regards to motor neurons derived from patient induced pluripotent stem cells. Compartmentalized microfluidic chambers are powerful tools for studying the distal axons of human induced pluripotent stem cells-derived motor neurons, and have recently been used to demonstrate striking regeneration defects in human motor neurons harboring ALS disease-causing mutations. Modeling the human neuromuscular circuit with human induced pluripotent stem cells-derived motor neurons will be critical for developing drugs that enhance axonal regeneration, sprouting, and reinnervation of neuromuscular junctions. In this review we will discuss compensatory axonal sprouting as a potential therapeutic target for ALS, and the use of compartmentalized microfluidic devices to find drugs that enhance regeneration and axonal sprouting of motor axons.

1 January 2016 in Neuroscience
Verified
Journal Article
Closed access
CTC. Tallon
C. Tallon
KRK.A. Russell
K.A. Russell
SSS. Sakhalkar
S. Sakhalkar
NAN. Andrapallayal
N. Andrapallayal
MFMohamed H. Farah
Mohamed H. Farah

27 March 2015 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
CDChristine Í Dali
Christine Í Dali
NBNorman W. Barton
Norman W. Barton
MFMohamed H. Farah
Mohamed H. Farah
Mihai MoldovanMihai Moldovan
Mihai Moldovan
JMJan‐Eric Månsson
Jan‐Eric Månsson
CKChristian Krarup
Christian Krarup
Objective: Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder due to deficient activity of arylsulfatase A (ASA) that causes accumulation of sulfatide and lysosulfatide. The disorder is associated with demyelination and axonal loss in the central and peripheral nervous systems. The late infantile form has an early‐onset, rapidly progressive course with severe sensorimotor dysfunction. The relationship between the degree of nerve damage and (lyso)sulfatide accumulation is, however, not established.Methods: In 13 children aged 2–5 years with severe motor impairment, markedly elevated cerebrospinal fluid (CSF) and sural nerve sulfatide and lysosulfatide levels, genotype, ASA mRNA levels, residual ASA, and protein cross‐reactive immunological material (CRIM) confirmed the diagnosis. We studied the relationship between (lyso)sulfatide levels and (1) the clinical deficit in gross motor function (GMFM‐88), (2) median and peroneal nerve motor and median and sural nerve sensory conduction studies (NCS), (3) median and tibial nerve somatosensory evoked potentials (SSEPs), (4) sural nerve histopathology, and (5) brain MR spectroscopy.Results: Eleven patients had a sensory‐motor demyelinating neuropathy on electrophysiological testing, whereas two patients had normal studies. Sural nerve and CSF (lyso)sulfatide levels strongly correlated with abnormalities in electrophysiological parameters and large myelinated fiber loss in the sural nerve, but there were no associations between (lyso)sulfatide levels and measures of central nervous system (CNS) involvement (GMFM‐88 score, SSEP, and MR spectroscopy).Interpretation: Nerve and CSF sulfatide and lysosulfatide accumulation provides a marker of disease severity in the PNS only; it does not reflect the extent of CNS involvement by the disease process. The magnitude of the biochemical disturbance produces a continuously graded spectrum of impairments in neurophysiological function and sural nerve histopathology.

27 January 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYing Liu
Ying Liu
BSBlessan Sebastian
Blessan Sebastian
BLBen Liu
Ben Liu
YZYiyue Zhang
Yiyue Zhang
JFJohn A. Fissel
John A. Fissel
MFMohamed H. Farah
Mohamed H. Farah
Sensory and autonomic neuropathy affects the majority of type II diabetic patients. Clinically, autonomic evaluation often focuses on sudomotor function yet this is rarely assessed in animal models. We undertook morphological and functional studies to assess large myelinated and small unmyelinated axons in the db/db type II diabetes mouse model. We observed that autonomic innervation of sweat glands in the footpads was significantly reduced in db/db mice compared to control db/+ mice and this deficit was greater compared to reductions in intraepidermal sensory innervation of adjacent epidermis. Additionally, db/db mice formed significantly fewer sweat droplets compared to controls as early as 6 weeks of age, a time when no statistical differences were observed electrophysiologically between db/db and db/+ mice studies of large myelinated sensory and motor nerves. The rate of sweat droplet formation was significantly slower and the sweat droplet size larger and more variable in db/db mice compared to controls. Whereas pilocarpine and glycopyrrolate increased and decreased sweating, respectively, in 6 month-old controls, db/db mice did not respond to pharmacologic manipulations. Our findings indicate autonomic neuropathy is an early and prominent deficit in the db/db model and have implications for the development of therapies for peripheral diabetic neuropathy.